vs

Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and Seadrill Ltd (SDRL). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $273.0M, roughly 1.8× Seadrill Ltd). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -3.7%, a 10.5% gap on every dollar of revenue. Over the past eight quarters, Pediatrix Medical Group, Inc.'s revenue compounded faster (-0.1% CAGR vs -8.9%).

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

Seadrill is an offshore drilling contractor providing worldwide offshore drilling services to the oil and gas industry. Its primary business is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deep water in both benign and harsh environments. It provides a contract-based service and primarily serves the oil super-majors, integrated oil and gas, state-owned national oil, and independent oil and gas companies.

MD vs SDRL — Head-to-Head

Bigger by revenue
MD
MD
1.8× larger
MD
$493.8M
$273.0M
SDRL
Higher net margin
MD
MD
10.5% more per $
MD
6.8%
-3.7%
SDRL
Faster 2-yr revenue CAGR
MD
MD
Annualised
MD
-0.1%
-8.9%
SDRL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MD
MD
SDRL
SDRL
Revenue
$493.8M
$273.0M
Net Profit
$33.7M
$-10.0M
Gross Margin
Operating Margin
9.9%
-1.1%
Net Margin
6.8%
-3.7%
Revenue YoY
-1.7%
Net Profit YoY
10.5%
EPS (diluted)
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MD
MD
SDRL
SDRL
Q4 25
$493.8M
$273.0M
Q3 25
$492.9M
$280.0M
Q2 25
$468.8M
$288.0M
Q1 25
$458.4M
$248.0M
Q4 24
$502.4M
Q3 24
$511.2M
$263.0M
Q2 24
$504.3M
$267.0M
Q1 24
$495.1M
$275.0M
Net Profit
MD
MD
SDRL
SDRL
Q4 25
$33.7M
$-10.0M
Q3 25
$71.7M
$-11.0M
Q2 25
$39.3M
$-42.0M
Q1 25
$20.7M
$-14.0M
Q4 24
$30.5M
Q3 24
$19.4M
$32.0M
Q2 24
$-153.0M
$253.0M
Q1 24
$4.0M
$60.0M
Operating Margin
MD
MD
SDRL
SDRL
Q4 25
9.9%
-1.1%
Q3 25
13.8%
9.3%
Q2 25
12.8%
2.1%
Q1 25
7.0%
7.3%
Q4 24
7.8%
Q3 24
6.6%
17.9%
Q2 24
-31.3%
Q1 24
3.2%
29.1%
Net Margin
MD
MD
SDRL
SDRL
Q4 25
6.8%
-3.7%
Q3 25
14.5%
-3.9%
Q2 25
8.4%
-14.6%
Q1 25
4.5%
-5.6%
Q4 24
6.1%
Q3 24
3.8%
12.2%
Q2 24
-30.3%
94.8%
Q1 24
0.8%
21.8%
EPS (diluted)
MD
MD
SDRL
SDRL
Q4 25
$0.40
Q3 25
$0.84
$-0.17
Q2 25
$0.46
$-0.68
Q1 25
$0.24
$-0.23
Q4 24
$0.37
Q3 24
$0.23
$0.49
Q2 24
$-1.84
$3.49
Q1 24
$0.05
$0.81

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MD
MD
SDRL
SDRL
Cash + ST InvestmentsLiquidity on hand
$375.2M
$339.0M
Total DebtLower is stronger
$570.5M
$613.0M
Stockholders' EquityBook value
$865.9M
$2.9B
Total Assets
$2.2B
$3.9B
Debt / EquityLower = less leverage
0.66×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MD
MD
SDRL
SDRL
Q4 25
$375.2M
$339.0M
Q3 25
$340.1M
$402.0M
Q2 25
$224.7M
$393.0M
Q1 25
$99.0M
$404.0M
Q4 24
$229.9M
Q3 24
$103.8M
Q2 24
$19.4M
$835.0M
Q1 24
$8.0M
Total Debt
MD
MD
SDRL
SDRL
Q4 25
$570.5M
$613.0M
Q3 25
$577.2M
$612.0M
Q2 25
$583.9M
$612.0M
Q1 25
$590.5M
$611.0M
Q4 24
$597.1M
Q3 24
Q2 24
$609.0M
Q1 24
Stockholders' Equity
MD
MD
SDRL
SDRL
Q4 25
$865.9M
$2.9B
Q3 25
$890.7M
$2.9B
Q2 25
$833.8M
$2.9B
Q1 25
$789.2M
$2.9B
Q4 24
$764.9M
Q3 24
$732.5M
$2.9B
Q2 24
$706.5M
$3.1B
Q1 24
$856.2M
$2.9B
Total Assets
MD
MD
SDRL
SDRL
Q4 25
$2.2B
$3.9B
Q3 25
$2.2B
$4.1B
Q2 25
$2.1B
$4.1B
Q1 25
$2.0B
$4.1B
Q4 24
$2.2B
Q3 24
$2.1B
Q2 24
$2.0B
$4.3B
Q1 24
$2.2B
Debt / Equity
MD
MD
SDRL
SDRL
Q4 25
0.66×
0.21×
Q3 25
0.65×
0.21×
Q2 25
0.70×
0.21×
Q1 25
0.75×
0.21×
Q4 24
0.78×
Q3 24
Q2 24
0.20×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MD
MD
SDRL
SDRL
Operating Cash FlowLast quarter
$114.1M
$-40.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.39×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MD
MD
SDRL
SDRL
Q4 25
$114.1M
$-40.0M
Q3 25
$137.3M
$28.0M
Q2 25
$137.2M
$11.0M
Q1 25
$-117.5M
$-27.0M
Q4 24
$133.0M
Q3 24
$91.8M
$-27.0M
Q2 24
$107.0M
$79.0M
Q1 24
$-125.2M
$29.0M
Cash Conversion
MD
MD
SDRL
SDRL
Q4 25
3.39×
Q3 25
1.91×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
4.72×
-0.84×
Q2 24
0.31×
Q1 24
-31.03×
0.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

SDRL
SDRL

Segment breakdown not available.

Related Comparisons